Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia.

Moraes LN, Fernandez GJ, Vechetti-Júnior IJ, Freire PP, Souza RWA, Villacis RAR, Rogatto SR, Reis PP, Dal-Pai-Silva M, Carvalho RF.

Sci Rep. 2017 Aug 1;7(1):6998. doi: 10.1038/s41598-017-07236-2.

2.

Metabolic profiles in heart failure due to non-ischemic cardiomyopathy at rest and under exercise.

Mueller-Hennessen M, Sigl J, Fuhrmann JC, Witt H, Reszka R, Schmitz O, Kastler J, Fischer JJ, Müller OJ, Giannitsis E, Weis T, Frey N, Katus HA.

ESC Heart Fail. 2017 May;4(2):178-189. doi: 10.1002/ehf2.12133. Epub 2017 Mar 8.

3.

Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.

Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D, Schultz MK, Packer M, Anker SD.

J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):549-556. doi: 10.1002/jcsm.12191. Epub 2017 Feb 27.

4.

Malnutrition and Gut Flora Dysbiosis: Specific Therapies for Emerging Comorbidities in Heart Failure.

Pasini E, Aquilani R, Corsetti G, Dioguardi FS.

Biomed Res Int. 2015;2015:382585. doi: 10.1155/2015/382585. Epub 2015 Sep 30. Review.

5.

Improved Ventilatory Efficiency with Locomotor Muscle Afferent Inhibition is Strongly Associated with Leg Composition in Heart Failure.

Keller-Ross ML, Johnson BD, Carter RE, Joyner MJ, Eisenach JH, Curry TB, Olson TP.

Int J Cardiol. 2016 Jan 1;202:159-66. doi: 10.1016/j.ijcard.2015.08.212. Epub 2015 Aug 29.

6.

Effects of exercise training on neurovascular control and skeletal myopathy in systolic heart failure.

Negrao CE, Middlekauff HR, Gomes-Santos IL, Antunes-Correa LM.

Am J Physiol Heart Circ Physiol. 2015 Apr 15;308(8):H792-802. doi: 10.1152/ajpheart.00830.2014. Epub 2015 Feb 13. Review.

7.

Plasma amino acid profiling identifies specific amino acid associations with cardiovascular function in patients with systolic heart failure.

Hakuno D, Hamba Y, Toya T, Adachi T.

PLoS One. 2015 Feb 6;10(2):e0117325. doi: 10.1371/journal.pone.0117325. eCollection 2015.

8.

Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones.

Josiak K, Jankowska EA, Piepoli MF, Banasiak W, Ponikowski P.

J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):287-96. doi: 10.1007/s13539-014-0152-z. Epub 2014 Aug 1.

9.

Cancer cachexia: impact, mechanisms and emerging treatments.

Vaughan VC, Martin P, Lewandowski PA.

J Cachexia Sarcopenia Muscle. 2013 Jun;4(2):95-109. doi: 10.1007/s13539-012-0087-1. Epub 2012 Oct 25.

10.

Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model.

O'Connor CM, Whellan DJ, Wojdyla D, Leifer E, Clare RM, Ellis SJ, Fine LJ, Fleg JL, Zannad F, Keteyian SJ, Kitzman DW, Kraus WE, Rendall D, Piña IL, Cooper LS, Fiuzat M, Lee KL.

Circ Heart Fail. 2012 Jan;5(1):63-71. doi: 10.1161/CIRCHEARTFAILURE.111.963462. Epub 2011 Nov 23.

11.

Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle.

Cicoira M, Anker SD, Ronco C.

J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):135-142. Epub 2011 Aug 24.

12.

Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?

DeBoer MD.

Mol Cell Endocrinol. 2011 Jun 20;340(1):97-105. doi: 10.1016/j.mce.2011.02.012. Epub 2011 Feb 25. Review.

13.

Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions.

Reichart DL, Hinkle RT, Lefever FR, Dolan ET, Dietrich JA, Sibley DR, Isfort RJ.

BMC Musculoskelet Disord. 2011 Jan 26;12:27. doi: 10.1186/1471-2474-12-27.

14.

Update on melanocortin interventions for cachexia: progress toward clinical application.

DeBoer MD.

Nutrition. 2010 Feb;26(2):146-51. doi: 10.1016/j.nut.2009.07.003. Epub 2009 Dec 8. Review.

15.

Chronic heart failure and exercise intolerance: the hemodynamic paradox.

Nilsson KR, Duscha BD, Hranitzky PM, Kraus WE.

Curr Cardiol Rev. 2008 May;4(2):92-100. doi: 10.2174/157340308784245757.

16.

Comparison of skeletal muscle strength between cardiac patients and age-matched healthy controls.

Baum K, Hildebrandt U, Edel K, Bertram R, Hahmann H, Bremer FJ, Böhmen S, Kammerlander C, Serafin M, Rüther T, Miche E.

Int J Med Sci. 2009 Jul 6;6(4):184-91.

17.

Nutritional and anti-inflammatory interventions in chronic heart failure.

Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC.

Am J Cardiol. 2008 Jun 2;101(11A):89E-103E. doi: 10.1016/j.amjcard.2008.03.007. Review.

20.

Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status.

Spruit MA, Thomeer MJ, Gosselink R, Troosters T, Kasran A, Debrock AJ, Demedts MG, Decramer M.

Thorax. 2005 Jan;60(1):32-8.

Supplemental Content

Support Center